These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 30338502)

  • 21. Prescription of lipid-lowering medications for patients with type 2 diabetes mellitus and risk-associated LDL cholesterol: a nationwide study of guideline adherence from the Swedish National Diabetes Register.
    Karlsson SA; Franzén S; Svensson AM; Miftaraj M; Eliasson B; Andersson Sundell K
    BMC Health Serv Res; 2018 Nov; 18(1):900. PubMed ID: 30486824
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Long-term secondary prevention of acute myocardial infarction (SEPAT) - guidelines adherence and outcome.
    Ergatoudes C; Thunström E; Rosengren A; Björck L; Bengtsson Boström K; Falk K; Fu M
    BMC Cardiovasc Disord; 2016 Nov; 16(1):226. PubMed ID: 27855640
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cardiovascular Disease in Women: Primary and Secondary Cardiovascular Disease Prevention.
    Sanghavi M; Gulati M
    Obstet Gynecol Clin North Am; 2016 Jun; 43(2):265-85. PubMed ID: 27212092
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Secondary Prevention of Cardiovascular Disease in Patients With Type 2 Diabetes Mellitus: International Insights From the TECOS Trial (Trial Evaluating Cardiovascular Outcomes With Sitagliptin).
    Pagidipati NJ; Navar AM; Pieper KS; Green JB; Bethel MA; Armstrong PW; Josse RG; McGuire DK; Lokhnygina Y; Cornel JH; Halvorsen S; Strandberg TE; Delibasi T; Holman RR; Peterson ED;
    Circulation; 2017 Sep; 136(13):1193-1203. PubMed ID: 28626088
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Secondary prevention of coronary artery disease in contemporary clinical practice.
    Jankowski P; Czarnecka D; Wolfshaut-Wolak R; Łysek R; Łukaszewska A; Bogacki P; Grodecki J; Mirek-Bryniarska E; Nessler J; Podolec P; Kawecka-Jaszcz K; Pająk A
    Cardiol J; 2015; 22(2):219-26. PubMed ID: 25299500
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [The best of epidemiology and cardiovascular prevention in 2006].
    Thomas D; Collet JP; Cottin Y; Cournot M; Ducimetière P; Ferrières J; Paillard F; Valensi P; Zeller M; Cambou JP
    Arch Mal Coeur Vaiss; 2007 Jan; 100 Spec No 1():57-64. PubMed ID: 17405566
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Dual antiplatelet therapy for primary and secondary prevention.
    Mathur AP; Waller AH; Dhruvakumar S; Mazza V; Gerula C; Maher J; Klapholz M; Kaluski E
    Minerva Cardioangiol; 2012 Dec; 60(6):611-28. PubMed ID: 23147438
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Recommendations for the control of cholesterolemia in Spain].
    Villar Alvarez F; Mata López P; Plaza Pérez I; Pérez Jiménez F; Maiques Galán A; Casasnovas Lenguas JA; Banegas Banegas JR; Abadal LT; Rodríguez Artalejo F; Gil López E
    Rev Esp Salud Publica; 2000; 74(5-6):457-74. PubMed ID: 11217236
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Efficacy over time of a short overall atherosclerosis management programme on the reduction of cardiovascular risk in patients after an acute coronary syndrome.
    Lafitte M; Pradeau V; Leroux L; Richeboeuf V; Tastet S; Boulon C; Paviot B; Bonnet J; Couffinhal T
    Arch Cardiovasc Dis; 2009 Jan; 102(1):51-8. PubMed ID: 19233109
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Disparities between prescribing of secondary prevention therapies for stroke and coronary artery disease in general practice.
    Heeley E; Anderson C; Patel A; Cass A; Peiris D; Weekes A; Chalmers J
    Int J Stroke; 2012 Dec; 7(8):649-54. PubMed ID: 21978147
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cardiovascular prevention: components, levels, early origins, and metrics.
    Kones R; Rumana U
    Hosp Pract (1995); 2014 Aug; 42(3):84-95. PubMed ID: 25255410
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [2016 European guidelines on cardiovascular disease prevention in clinical practice. The Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of 10 societies and by invited experts. Developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation].
    Piepoli MF; Hoes AW; Agewall S; Albus C; Brotons C; Catapano AL; Cooney MT; Corrà U; Cosyns B; Deaton C; Graham I; Hall MS; Hobbs FDR; Løchen ML; Löllgen H; Marques-Vidal P; Perk J; Prescott E; Redon J; Richter DJ; Sattar N; Smulders Y; Tiberi M; van der Worp HB; van Dis I; Verschuren WMM
    G Ital Cardiol (Rome); 2017; 18(7):547-612. PubMed ID: 28714997
    [No Abstract]   [Full Text] [Related]  

  • 33. Cardiovascular disease guideline adherence and self-reported statin use in longstanding type 1 diabetes: results from the Canadian study of longevity in diabetes cohort.
    Bai JW; Boulet G; Halpern EM; Lovblom LE; Eldelekli D; Keenan HA; Brent M; Paul N; Bril V; Cherney DZ; Weisman A; Perkins BA
    Cardiovasc Diabetol; 2016 Jan; 15():14. PubMed ID: 26809442
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Primary and secondary prevention of coronary heart disease. Evidence offers multiple strategies.
    Lynn MM
    Adv Nurse Pract; 2000 Jun; 8(6):36-41; quiz 42-3. PubMed ID: 15658206
    [No Abstract]   [Full Text] [Related]  

  • 35. [Primary and secondary prevention of the acute coronary syndrome].
    Weingärtner O; Laufs U
    Hamostaseologie; 2006 May; 26(2):158-66; quiz 167-8. PubMed ID: 16676060
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Secondary prevention in patients after hospitalisation due to coronary artery disease: what has changed since 2006?
    Jankowski P; Czarnecka D; Lysek R; Skrzek A; Smaś-Suska M; Mazurek A; Brzozowska-Kiszka M; Wolfshaut-Wolak R; Surowiec S; Bogacki P; Bryniarska-Mirek E; Bryniarski L; Grodecki J; Nessler J; Olszowska M; Podolec P; Kawecka-Jaszcz K; Pająk A
    Kardiol Pol; 2014; 72(4):355-62. PubMed ID: 24408064
    [TBL] [Abstract][Full Text] [Related]  

  • 37. EMPA-REG and Other Cardiovascular Outcome Trials of Glucose-lowering Agents: Implications for Future Treatment Strategies in Type 2 Diabetes Mellitus.
    Schernthaner G; Schernthaner-Reiter MH; Schernthaner GH
    Clin Ther; 2016 Jun; 38(6):1288-1298. PubMed ID: 27210264
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Evidence-based guideline of the German Nutrition Society: carbohydrate intake and prevention of nutrition-related diseases.
    Hauner H; Bechthold A; Boeing H; Brönstrup A; Buyken A; Leschik-Bonnet E; Linseisen J; Schulze M; Strohm D; Wolfram G;
    Ann Nutr Metab; 2012; 60 Suppl 1():1-58. PubMed ID: 22286913
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [An updated overview of the high intensity lipid lowering therapy in high cardiovascular risk patients].
    Pedro-Botet J; Pintó X
    Clin Investig Arterioscler; 2016; 28(1):19-30. PubMed ID: 26657098
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Modern cardiac rehabilitation: Integrating the best measures to reduce a second cardiac event.
    Armbruster RA; Lim MJ
    Mo Med; 2013; 110(2):154-8. PubMed ID: 23724492
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.